BEIJING -- China will establish a national collaborative network of hospitals for rare disease diagnosis and treatment to promote the early detection and effective treatment of such diseases, according to a decision by the National Health Commission (NHC). Comprised of 324 hospitals selected for their capacity and experience in treating patients with rare diseases, the network will facilitate the timely transfer of difficult and complicated cases between hospitals and the allocation of quality medical resources for them, an NHC statement says. Meanwhile, hospitals in the network are urged to further train medical workers on rare disease knowledge and clinical skills, focusing on improving their abilities to identify, diagnose and treat such cases. China will establish a system for rare disease patients to be registered, the NHC adds. crossfit silicone wristbandsembossed-wristbandfigured wristbandmiscarriage awareness silicone braceletsdual-layer-wristbandblank wristbandcolored rubber bands for braceletsplain black silicone wristbandssilicone wristbands
[Photo/VCG] BEIJING -- Changsheng Bio-technology, a major Chinese vaccine maker, has received notice of a mandatory delisting from the Shenzhen Stock Exchange, the company said in a statement Tuesday. According to the statement, the Shenzhen bourse has decided to move ahead with mandatory delisting procedures after starting preparations in November over major law violations of Changsheng's major subsidiary Changchun Changsheng Life Sciences Limited. Changsheng shares will resume trading Wednesday for 30 trading days marked by delisting risk warnings before entering a six-month suspension, which will pave the way for ultimate removal from the Shenzhen exchange. In October, authorities revoked the pharmaceutical production license and imposed a fine of more than 9.1 billion yuan ($1.32 billion) on Changchun Changsheng Life Sciences Limited for the illegal production of vaccines.
